Showing results (211-220 of 350) with videos related to
Sort By:
Pageof 35
Brain Research|October 14, 1996
MK-801 prevents levodopa-induced motor response alterations in parkinsonian ratsC Marin, S Papa, T M Engber, et al.Brain Research|July 16, 1990
Responses of substantia nigra pars reticulata neurons to GABA and SKF 38393 in 6-hydroxydopamine-lesioned rats are differentially affected by continuous and intermittent levodopa administrationB G Weick, T M Engber, Z Susel, et al.Journal of Neurology, Neurosurgery, and Psychiatry|December 1, 1983
Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's diseaseR Durso, C A Tamminga, S Ruggeri, et al.Journal of Neurochemistry|August 1, 1985
Demonstration and distribution of kassinin-like material (substance K) in the rat central nervous systemC W Shults, H Yajima, H G Gullner, et al.Neurology|October 1, 1987
Dopaminergic mechanisms in hemiparkinsonian monkeysP Barone, K S Bankiewicz, G U Corsini, et al.Movement Disorders : Official Journal of the Movement Disorder Society|May 1, 1996
Assessment of coenzyme Q10 tolerability in Huntington's diseaseA Feigin, K Kieburtz, P Como, et al.Journal of the Neurological Sciences|May 1, 1994
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomographyJ Blin, M F Piercey, M E Giuffra, et al.Neurology|October 1, 1993
End-of-dose dystonia in Parkinson's diseaseD Bravi, M M Mouradian, J W Roberts, et al.Acta Neuropathologica|October 1, 1996
Coexistence of Huntington's disease and familial amyotrophic lateral sclerosis: case presentationA Rubio, K Steinberg, D A Figlewicz, et al.Pageof 35